Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 5/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.34 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2342694 | 0.87 | LPAR1 (0.43) | MAPTPTGER4CYSLTR2CYSLTR1 | |
| SCHEMBL1245272 | 0.83 | SCN9A (0.45) | SCN9ASCN5ANPC1NTRK1MAPT | |
| SCHEMBL1245064 | 0.81 | SCN9A (0.48) | SCN9ASCN5ANPC1NTRK1MAPT | |
| SCHEMBL9903605 | 0.81 | NPSR1 (0.43) | NTRK1MAPTNPSR1PTGER4CYSLTR2 | |
| SCHEMBL1247388 | 0.81 | SCN9A (0.42) | SCN9ASCN5ANPC1NTRK1MAPT | |
| SCHEMBL1246321 | 0.78 | NTRK1 (0.45) | SCN9ASCN5ANPC1NTRK1MAPT | |
| SCHEMBL1247390 | 0.78 | SCN9A (0.44) | SCN9ASCN5ANPC1NTRK1MAPT | |
| SCHEMBL1246243 | 0.78 | SCN9A (0.44) | SCN9ASCN5ANPC1NTRK1MAPT | |
| SCHEMBL2364482 | 0.78 | LPAR1 (0.48) | SCN9ASCN5AMAPTPTGER4 | |
| SCHEMBL1247570 | 0.77 | SCN9A (0.46) | SCN9ASCN5ANPC1NTRK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011017350-A2 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | WO | claimed |